Brief: Neximmune, Zephyr Ai Announce Strategic Partnership In Oncology For Target Discovery And Validation
17/03/2022 11:31
March 17 (Reuters) - Neximmune Inc NEXI.O :
* NEXIMMUNE AND ZEPHYR AI ANNOUNCE A STRATEGIC PARTNERSHIP
IN
ONCOLOGY FOR TARGET DISCOVERY AND VALIDATION
* NEXIMMUNE - ZEPHYR TO EMPLOY PROPRIETARY AI & MACHINE
LEARNING
TECHNOLOGY TO IDENTIFY TARGETS SUITABLE FOR ACTIVATING
T-CELL-MEDIATED ANTI-TUMOR RESPONSES
Source text for Eikon: ID:nGNX3gxcn9
Further company coverage: NEXI.O
Recent news on Neximmune
See all newsBrief: Neximmune Appointed Albert Marchio As Interim CFO
Brief: NexImmune and Agents Agreed To Terminate Sales Agreement & ATM Program dated June 2022
Brief: NexImmune Says Co Expects Existing Cash And Cash Equivalents Will Be Sufficient To Meet Its Anticipated Cash Requirements Through Mid-February 2024
Brief: Neximmune Gets Notice From Listing Qualifications Department Of Nasdaq
Brief: NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting